diaDexus Revenue and Competitors
Estimated Revenue & Valuation
- diaDexus's estimated annual revenue is currently $4.3M per year.
- diaDexus's estimated revenue per employee is $155,000
Employee Data
- diaDexus has 28 Employees.
- diaDexus grew their employee count by 0% last year.
diaDexus's People
Name | Title | Email/Phone |
---|
diaDexus Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is diaDexus?
A Multi-Product Company Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker's utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.
keywords:N/AN/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
diaDexus News
... Alere/Biosite/Inverness, Axis-Shield, Beckman Coulter/Danaher, Becton Dickinson, Bio/Data, Decode Genetics, Diadexus.
Professional Key players: Abbott, Roche Diagnostics, BG Medicine, Biomerieux, Critical Diagnostics, DiaDexus, Response Biomedical, Siemens Healthcare,...
... joining Quest he held leadership, business development and strategy roles in molecular diagnostics at SmithKline Beecham and diaDexus.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2M | 28 | 33% | $7M |
#2 | $4.1M | 28 | -3% | N/A |
#3 | $2.8M | 28 | N/A | N/A |
#4 | $5.3M | 28 | N/A | N/A |
#5 | $2.8M | 28 | N/A | N/A |